Tigecycline Basics and Metabolism Overview
Tigecycline, a glycylcycline antibiotic, undergoes minimal renal clearance and primarily hepatic metabolism via Phase II glucuronidation and biliary excretion, with fecal elimination accounting for about 59% of the dose. Its pharmacokinetics show high volume of distribution (7-10 L/kg), driven by extensive tissue penetration.[1]
How Obesity Alters Tigecycline PK
Obese patients exhibit increased tigecycline clearance (CL) and volume of distribution (Vd), leading to lower plasma concentrations compared to normal-weight individuals. Studies in morbidly obese adults (BMI >40 kg/m²) report 25-40% higher CL (e.g., 28.5 L/h vs. 20.1 L/h in non-obese) and Vd (e.g., 12.5 L/kg vs. 8.9 L/kg), resulting in reduced AUC (area under the curve) by 20-30%. Half-life remains similar (15-20 hours), but peak concentrations drop due to expanded body mass.[2][3]
Why Obesity Drives These Changes
Obese individuals have higher cardiac output, increased hepatic blood flow, and expanded adipose tissue, enhancing drug distribution and biliary/fecal elimination. Glucuronidation enzymes (e.g., UGT1A1) show no obesity-related induction, but overall clearance rises with body weight metrics like total body weight (TBW) or fat-free mass. Simulations confirm dosing by TBW overestimates exposure in obesity.[4]
Dosing Adjustments in Obese Patients
Standard 100 mg loading dose followed by 50 mg IV q12h underdoses obese patients, risking subtherapeutic levels for infections like complicated skin/skin structure or intra-abdominal. Guidelines suggest 100 mg q12h maintenance using adjusted body weight or TBW caps (e.g., ≤120 kg). Population PK models recommend 75-100 mg q12h for BMI >30 to achieve fT>MIC targets.[2][5]
Clinical Evidence from Studies
- Nested case-control in 100+ ICU patients: Obese had 35% lower AUC/MIC ratios.[3]
- Prospective trial (n=30 morbidly obese): CL scaled best to TBW; standard dosing yielded 22% lower steady-state concentrations.[2]
No large RCTs exist; data from observational cohorts and Monte Carlo simulations highlight efficacy risks for resistant pathogens (e.g., Acinetobacter).[6]
Potential Risks and Monitoring
Underdosing in obesity correlates with treatment failure (OR 2.1 for BMI >35). Monitor trough levels (>1 mg/L) or AUC via Bayesian forecasting. No hepatic adjustment needed unless dysfunction present, but obesity amplifies variability from inflammation or critical illness.[5]
Sources
[1]: Tigecycline FDA Label
[2]: Pai MP et al., Antimicrob Agents Chemother (2011) - Obese PK study
[3]: Skosnik-Vallejo et al., J Antimicrob Chemother (2020) - ICU obesity analysis
[4]: Roberts JA et al., Clin Pharmacokinet (2014) - Obesity PK review
[5]: IDSA Guidelines (2017, updated) - Tigecycline dosing
[6]: Bulik CC et al., Antimicrob Agents Chemother (2011) - Monte Carlo simulation